Roapac Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Roapac Next-Generation Sequencing (NGS) Services Market was valued at $72 Million in 2017 and projected to reach to $200.3 Million by 2022, representing a compound annual growth rate of 22.7%. Roapac's NGS services market is positioned for continued robust expansion beyond 2022, supported by increasing healthcare digitalization, rising cancer incidence rates, and growing government support for genomic medicine initiatives.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Roapac Next-Generation Sequencing (NGS) Services Market Trends and Insights
- Roapac's 22.7% compound annual growth rate significantly outpaced global trends, reflecting accelerating adoption of genomic sequencing technologies across the region.
- This acceleration in Roapac is driven by increasing healthcare investments, rising prevalence of genetic disorders, and growing demand for personalized medicine solutions. Roapac's NGS services market benefited from expanding research infrastructure and improving access to advanced diagnostic capabilities throughout the forecast period.
- The region's strong pharmaceutical and biotechnology sectors positioned Roapac as a critical hub for genomic research and clinical applications.
- Roapac's market growth was further supported by declining sequencing costs, regulatory framework improvements, and heightened awareness among healthcare providers regarding the clinical utility of NGS-based diagnostics and therapeutics..
Key Market Statistics
- CAGR (2017-2022) 22.7% CAGR
- Market Size, 2017 ~USD 72 Million
- Forecast, 2022 ~USD 200.3 Million
- Country Roapac
Roapac Next-Generation Sequencing (NGS) Services Market Overview
Exceptional Regional Growth :
Roapac's NGS services market achieved a 22.7% CAGR from 2017-2022, outperforming the global average of 21%, demonstrating the region's accelerated adoption of genomic sequencing technologies and strong market momentum.
Significant Market Expansion :
The market grew from $72.0 million in 2017 to $200.3 million by 2022, representing a 178% increase over five years and reflecting increasing investment in precision medicine and genomic research infrastructure across Roapac.
Regional Leadership Position :
Roapac's outpacing of global CAGR indicates the region is becoming a key hub for NGS service adoption, driven by rising healthcare expenditure, growing prevalence of genetic disorders, and expanding research capabilities.
Sustained Market Trajectory :
The consistent 22.7% annual growth rate suggests strong underlying demand drivers in Roapac, including increased clinical adoption, government genomics initiatives, and growing pharmaceutical and biotech sector investments in the region.
Roapac Next-Generation Sequencing (NGS) Services Market Dynamics
- The region's strong CAGR trajectory indicates sustained investment in sequencing infrastructure and expanding clinical applications across oncology, rare disease diagnosis, and personalized medicine.
- Healthcare providers and research institutions in Roapac are increasingly recognizing NGS as essential for precision diagnostics and treatment planning.
- Emerging economies within the region are rapidly adopting these technologies, while established markets continue to deepen clinical integration.
- Competitive pricing, improved accessibility, and growing local expertise are expected to further accelerate market penetration and drive continued double-digit growth through the coming years..
Market Ecosystem
NGS SERVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Commercial NGS services covering clinical whole-genome sequencing, exome sequencing, RNA sequencing, targeted sequencing, 16S microbiome profiling, and metagenomics for clinical research, precision medicine, and microbial studies. | Integrated sequencing and bioinformatics | CAP/CLIA-validated clinical options | Customizable workflows for diverse applications |
 |
WGS, WES, transcriptome, metagenome, epigenome, and single-cell sequencing services used in disease research, biomarker discovery, precision medicine, population studies, and microbiome analysis. Services include sequencing and downstream bioinformatics. | Broad multi-omics service portfolio | High-throughput sequencing capacity | End-to-end sequencing and data analysis support |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Roapac's NGS services market is projected to grow from $72.0M (2017) to $200.3M (2022), representing a 22.7% CAGR.
- Roapac's growth rate exceeds the global average, driven by increased healthcare spending and genomic research investments.
- Roapac benefits from expanding pharmaceutical and biotechnology sectors that drive demand for NGS-based diagnostics and drug development.
- Declining sequencing costs and regulatory improvements in Roapac are accelerating clinical adoption of NGS services across the region.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Roapac Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Healthcare Providers & Hospital Networks : Need market intelligence to evaluate NGS service adoption, assess competitive landscape, and make informed decisions about integrating genomic sequencing capabilities into clinical operations across Roapac.
- Diagnostic & Sequencing Companies : Require detailed regional market data to identify expansion opportunities, understand customer demand patterns, and develop localized service offerings that capitalize on Roapac's high-growth trajectory.
- Pharmaceutical & Biotech Firms : Need insights into Roapac's genomic research infrastructure and precision medicine adoption to guide R&D investments, clinical trial planning, and companion diagnostic development strategies.
- Private Equity & Investment Firms : Seek validated market sizing and growth forecasts for Roapac to evaluate acquisition targets, assess portfolio company potential, and identify attractive investment opportunities in the NGS services sector.
- Government & Healthcare Policy Makers : Require market analysis to inform genomics initiatives, healthcare infrastructure planning, and regulatory frameworks that support precision medicine adoption and NGS service accessibility across Roapac.
Key Companies in the Roapac Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Identify High-Growth Opportunities : Understand Roapac's 22.7% CAGR trajectory to pinpoint emerging segments, service providers, and geographic pockets with the highest growth potential for market entry or expansion strategies.
- Benchmark Regional Performance : Compare Roapac's market dynamics against global trends (21% CAGR) to assess competitive positioning, market maturity, and relative attractiveness for investment and partnership decisions.
- Strategic Market Sizing : Leverage validated market data ($72M to $200.3M growth) to inform accurate financial projections, resource allocation, and business case development specific to Roapac operations.
- Competitive Intelligence : Gain insights into Roapac's unique adoption drivers, regulatory environment, and customer preferences to develop targeted go-to-market strategies and differentiated service offerings for the region.
- Risk Mitigation : Access comprehensive regional analysis to identify market barriers, regulatory challenges, and infrastructure gaps in Roapac, enabling informed risk assessment and contingency planning.
Frequently asked questions
What is the market size of NGS services in Roapac?
Roapac's NGS services market was valued at $72.0 million in 2017 and is forecasted to reach $200.3 million by 2022.
What is the CAGR for NGS services in Roapac?
Roapac's NGS services market is expected to grow at a compound annual growth rate of 22.7% from 2017 to 2022.
What factors are driving growth in Roapac's NGS market?
Roapac's NGS market growth is driven by increased healthcare investments, rising genetic disorder prevalence, declining sequencing costs, and growing demand for personalized medicine and genomic diagnostics.
How does Roapac's NGS market growth compare to global trends?
Roapac's 22.7% CAGR significantly exceeds the global average of 21%, indicating stronger regional adoption and investment in NGS technologies.
What role do pharmaceutical companies play in Roapac's NGS market?
Roapac's strong pharmaceutical and biotechnology sectors drive substantial demand for NGS services in drug development, clinical trials, and precision medicine applications.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global NGS services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with primary research inputs to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the NGS services market. The secondary sources used for this study include Centers for Disease Control and Prevention (CDC), National Human Genome Research Institute (NHGRI), International Chromosome and Genome Society (ICGS), European Society of Human Genetics (ESHG), Centre for Cellular & Molecular Biology (CCMB), European Medicines Agency (EMA), Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), World Health Organization (WHO), and United States Food & Drug Administration (USFDA). This also includes academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, among others. Secondary data were collected and analyzed to determine the overall size of the global NGS services market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, NGS refers to non-Sanger-based, high-throughput DNA and RNA sequencing technologies. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. The NGS services market encompasses outsourced sequencing and associated laboratory and bioinformatics services provided for comprehensive genomic and transcriptomic analysis. Services include pre-sequencing/sample preparation, library preparation, sequencing, data processing, bioinformatics analysis, and interpretation. The market covers sequencing services such as whole-genome sequencing (WGS), whole-exome sequencing (WES), RNA sequencing, targeted sequencing, and metagenomics/16S sequencing, supporting applications across oncology, infectious disease research, reproductive health, drug discovery, and other life science and clinical research areas.
NGS Services Market : Top-Down and Bottom-Up Approach
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Data center immersion cooling fluids are specialized liquids designed to efficiently dissipate heat from IT equipment by directly submerging electronic components in a thermally conductive but electrically non- conductive liquid. These fluids are crucial in immersion cooling technology, which offers higher energy efficiency, improved thermal management, and reduced operational costs compared to traditional air- based cooling systems. There are three major types of data center immersion cooling fluids: mineral oil- based, fluorocarbon-based, and synthetic fluids. Single-phase cooling and two-phase cooling are the two primary technologies used in data center immersion cooling. Single-phase cooling involves submerging IT equipment in a fluid that remains in a liquid state while absorbing heat. The heated fluid is then circulated through heat exchangers to dissipate the heat before being recirculated. Two-phase cooling, on the other hand, utilizes a fluid that undergoes a phase change, evaporating into vapor upon absorbing heat. The vapor is then condensed back into liquid form through a cooling system. These fluids play a crucial role in efficient thermal management, energy savings, sustainability, and hardware longevity, eliminating the need for extensive air conditioning while reducing carbon footprints.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Hospitals & clinical laboratories
- Academic & research institutes
- Contract research organizations (CROs)
- NGS sequencing service providers
- Genomics & bioinformatics companies
- Life science research organizations
- Government genomics programs & public health agencies
- Venture capitalists & investors
- Market research & consulting firms
- Medical institutions & universities
- Regulatory authorities
Report Objectives
- To define, describe, and forecast the NGS services market based on type, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall NGS services market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the NGS services market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as service launches, acquisitions, expansions, agreements, partnerships, and collaborations in the NGS services market
- To benchmark players within the NGS services market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Customization Options
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
The following customization options are available for the report:
- Additional country-level analysis of the data center immersion cooling fluids market
- Profiling of additional market players (up to 5)
Geographical Analysis
- Further breakdown of the Rest of Europe NGS services market, by country
- Further breakdown of the Rest of Asia Pacific NGS services market, by country
- Further breakdown of the Rest of Latin America NGS services market, by country
- Further breakdown of the Rest of Middle East NGS services market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
